- Home
- URGN vs IIIN Comparison
URGN vs IIIN Comparison
Compare URGN & IIIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- IIIN
- Stock Information
- Founded
- URGN 2004
- IIIN 1953
- Country
- URGN United States
- IIIN United States
- Employees
- URGN N/A
- IIIN N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- IIIN Steel/Iron Ore
- Sector
- URGN Health Care
- IIIN Industrials
- Exchange
- URGN Nasdaq
- IIIN Nasdaq
- Market Cap
- URGN 830.4M
- IIIN 745.7M
- IPO Year
- URGN 2017
- IIIN N/A
- Fundamental
- Price
- URGN $16.82
- IIIN $36.57
- Analyst Decision
- URGN Strong Buy
- IIIN
- Analyst Count
- URGN 8
- IIIN 0
- Target Price
- URGN $28.50
- IIIN N/A
- AVG Volume (30 Days)
- URGN 1.2M
- IIIN 81.3K
- Earning Date
- URGN 11-05-2025
- IIIN 10-16-2025
- Dividend Yield
- URGN N/A
- IIIN 3.06%
- EPS Growth
- URGN N/A
- IIIN 53.01
- EPS
- URGN N/A
- IIIN 1.59
- Revenue
- URGN $94,238,000.00
- IIIN $604,566,000.00
- Revenue This Year
- URGN $39.63
- IIIN $24.62
- Revenue Next Year
- URGN $111.49
- IIIN $7.01
- P/E Ratio
- URGN N/A
- IIIN $23.03
- Revenue Growth
- URGN 10.85
- IIIN 9.44
- 52 Week Low
- URGN $3.42
- IIIN $22.49
- 52 Week High
- URGN $21.71
- IIIN $41.64
- Technical
- Relative Strength Index (RSI)
- URGN 42.97
- IIIN 38.23
- Support Level
- URGN $15.86
- IIIN $37.91
- Resistance Level
- URGN $17.43
- IIIN $38.80
- Average True Range (ATR)
- URGN 1.06
- IIIN 0.87
- MACD
- URGN -0.15
- IIIN -0.22
- Stochastic Oscillator
- URGN 23.05
- IIIN 0.38
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About IIIN Insteel Industries Inc.
Insteel Industries Inc manufactures steel wire reinforcing products for concrete construction applications. It manufactures and markets PC strand and welded wire reinforcement, including ESM, concrete pipe reinforcement, and standard welded wire reinforcement. The company's products are sold to manufacturers of concrete products that are used in nonresidential construction. Its concrete reinforcing products consist of two product lines: PC strand and WWR. Insteel generates its geographical revenue from the United States.